Nature of Business (Details)			3 Months Ended
	Apr. 22, 2024 USD ($) $ / shares shares	Jan. 03, 2024 USD ($)	Mar. 31, 2024 USD ($) segment shares	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)
Nature of business:
Number of operating segments | segment			2
Net Income (Loss)			$ (1,915,327)	$ (1,046,109)
Net cash used in operating activities			(1,342,482)	(2,166,253)
Reclassification of Convertible Debt From Non-Current to current Liability			1,000,000
Number of shares sold				70,730
Cash and cash equivalents			7,091,548	10,265,850	$ 8,446,158	$ 13,359,615
Net decrease in cash			$ 1,354,610	3,093,765
Percentage change in cash and cash equivalent			16.00%
Accumulated deficit			$ 227,619,503		225,704,176
Working capital			607,499		$ 3,355,212
Working capital increase, decrease			$ (2,747,713)
Working capital increase (decrease) as a percent			82.00%
Common Stock, Shares, Issued | shares			10,524,437		10,378,238
Repayment of debt principal				1,000,000
Consideration paid recorded in general and administrative expense			$ 1,022,051	1,235,376
Common Stock
Nature of business:
Number of shares sold				$ 21
Subsequent Event
Nature of business:
Shares issued price per share | $ / shares	$ 0.40
Subsequent Event | Public Offering
Nature of business:
Total gross proceeds	$ 4,750,000
Shares issued price per share | $ / shares	$ 0.40
Exercise price of warrants | $ / shares	$ 0.001
Expiration term of warrants	5 years
Net proceeds	$ 4,300,000
Subsequent Event | Common Stock | Public Offering
Nature of business:
Number of shares issued | shares	3,275,000
Exercise price of warrants | $ / shares	$ 0.40
Pre-funded warrants | Subsequent Event | Public Offering
Nature of business:
Number of common warrants to purchase shares issued | shares	8,600,000
Exercise price of warrants | $ / shares	$ 0.001
Common warrants | Subsequent Event | Public Offering
Nature of business:
Number of common warrants to purchase shares issued | shares	11,875,000
Exercise price of warrants | $ / shares	$ 0.40
Expiration term of warrants	5 years
Convertible Debt
Nature of business:
Repayment of debt principal		$ 99,416
HyBryte
Nature of business:
Revenue from collaborative arrangement			$ 1,100,000
Term (in years)			4 years
NIH
Nature of business:
Government grant funding			$ 673,000,000,000